SynthesisFrontiers in immunology2025
Efficacy and safety of PARP inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Several clinical trials have explored the efficacy and safety of Poly (ADP-ribose) polymerase (PARP) inhibitors in endometrial cancer (EC). However, evidence supporting PARP inhibitors alone or in combination with other medications in advanced or recurrent EC remains limited. Methods: We utilized Cochrane Library, PubMed, Web of Science, and Embase to identify clinical trials that evaluated the efficacy and safety of PARP inhibitors in advanced and recurrent EC. The outcomes analyzed included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events (AEs). We computed hazard ratios (HRs) for PFS and OS, with 95% confidence intervals (CIs) from randomized trials. Subgroup analysis was conducted based on the PARP inhibitor combination therapy strategies (with antiprogrammed death 1 [PD-1]/antiprogrammed death ligand-1 [PD-L1] inhibitors or antiangiogenic agents). Results: Overall, 12 clinical trials for a total number of 1,594 patients diagnosed with advanced or recurrent EC were included in this meta-analysis. The duration of follow-up time ranged from a median of 7.4 to 31.9 months, and the pooled median PFS was 6.43 months. The results showed that the combination of PARP with PD-L1/PD-1 inhibitors could significantly prolong PFS versus placebo (hazard ratio [HR] = 0.567; 95% confidence interval [CI] = 0.469-0.686; Conclusion: The combination of a PARP inhibitor with a PD-L1/PD-1 inhibitor shows modest activity with substantial toxicity, particularly in heavily pretreated and largely pMMR populations. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024556356.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.